

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHUANGDENG GROUP CO., LTD.
雙登集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06960)

ADOPTION OF THE 2026 SHARE OPTION SCHEME

Reference is made to the circular (the “**Circular**”) of Shuangdeng Group Co., Ltd. (the “**Company**”) dated 4 May 2026 in respect of, among others, the proposal to adopt a H share option scheme (the “**2026 Share Option Scheme**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 2 June 2026, the Company has adopted the 2026 Share Option Scheme, which will be funded by both new H shares (the “**H Shares**”) and treasury shares (if any) of the Company (collectively the “**Shares**”).

The 2026 Share Option Scheme constitutes a share scheme involving the issuance of new H Shares by the Company under Chapter 17 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The provisions of the 2026 Share Option Scheme comply with Chapter 17 of the Listing Rules. Full details of the 2026 Share Option Scheme are set out in the Circular.

All conditions precedent to adoption of the 2026 Share Option Scheme have been fulfilled, and accordingly the 2026 Share Option Scheme was adopted on 2 June 2026.

By Order of the Board
SHUANGDENG GROUP CO., LTD.
(雙登集團股份有限公司)

Dr. Yang Rui

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 2 June 2026

As at the date of this announcement, the Board comprises (i) Dr. Yang Rui, Dr. Yang Baofeng and Ms. He Rong as executive Directors; (ii) Mr. Qian Shan'gao, Mr. Lou Zhiqiang and Ms. Hu Shuxuan as non-executive Directors; and (iii) Dr. Yin Junming, Dr. Wang Jin and Dr. Wang Xi as independent non-executive Directors.